Patrick J. Ward
Experienced in Testicular Cancer

Dr. Patrick J. Ward

Hematology Oncology | Oncology
4350 Malsbary Road, 
Blue Ash, OH 
On Staff At
Accepting New Patients
Experienced in Testicular Cancer
4350 Malsbary Road, 
Blue Ash, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Ward is a Hematologist Oncology specialist and an Oncologist in Blue Ash, Ohio. Dr. Ward is rated as an Experienced provider by MediFind in the treatment of Testicular Cancer. His top areas of expertise are Lung Cancer, Breast Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, and Tissue Biopsy. Dr. Ward is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Ohio State University College Of Medicine, 1997
Residency
Ohio State Wexner Medical Center, Internal Medicine, 2000
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in OH
Board Certifications
American Board Of Internal Medicine
Fellowships
Ohio State Medical Center, Hematology & Oncology, 2003
Hospital Affiliations
Mercy Health - Anderson Hospital
Mercy Health - West Hospital
The Jewish Hospital - Mercy Health
Mercy Health - Clermont Hospital
Mercy Health - Fairfield Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Oncology Hematology Care, Inc
4350 Malsbary Road, Blue Ash, OH 45242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Biological, Drug
Study Drugs: FR? vaccine, Cyclophosphamide
Study Phase: Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

35 Total Publications

A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 06, 2025
Similar Doctors
Advanced in Testicular Cancer
Dr. Robert A. Franklin
Hematology Oncology | Hospital Medicine
Advanced in Testicular Cancer
Dr. Robert A. Franklin
Hematology Oncology | Hospital Medicine

University Of Cincinnati Physicians Company LLC

7700 University Dr, 
West Chester, OH 
 (8.2 miles away)
513-298-7325
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Franklin is a Hematologist Oncology specialist and a Hospital Medicine provider in West Chester, Ohio. Dr. Franklin is rated as an Advanced provider by MediFind in the treatment of Testicular Cancer. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, and WT1-Related Wilms Tumor Syndromes. Dr. Franklin is currently accepting new patients.

Advanced in Testicular Cancer
Dr. Shamim Z. Jilani
Oncology | Hematology
Advanced in Testicular Cancer
Dr. Shamim Z. Jilani
Oncology | Hematology

Dayton Physicians LLC

8881 N Main St, 
Dayton, OH 
 (42.8 miles away)
937-293-1622
Experience:
44+ years
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Shamim Jilani is an Oncologist and a Hematologist in Dayton, Ohio. Dr. Jilani has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Testicular Cancer. Her top areas of expertise are Lung Cancer, Familial Colorectal Cancer, Colorectal Cancer, WT1-Related Wilms Tumor Syndromes, and Bone Marrow Aspiration. Dr. Jilani is currently accepting new patients.

Advanced in Testicular Cancer
Dr. Weiping Zang
Hematology | Oncology
Advanced in Testicular Cancer
Dr. Weiping Zang
Hematology | Oncology

Christ Hospital Medical Specialists Ii, LLC

2123 Auburn Ave, 
Cincinnati, OH 
 (10.5 miles away)
513-585-2323
Languages Spoken:
English
See accepted insurances

Weiping Zang is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Zang is rated as an Advanced provider by MediFind in the treatment of Testicular Cancer. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Thrombocytopenia, and Posterior Fossa Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ward's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 140 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile